ImmunoForge Achieves Milestone with IND Approval for Pemziviptadil and KF1601 in US and Korea ImmunoForge has secured IND approvals for Phase 2 trial of Pemziviptadil for DMD cardiomyopathy and Phase 1 trial for KF1601 targeting leukemia, marking critical progress.

ImmunoForge Achieves Milestone with IND Approval for Pemziviptadil and KF1601 in US and Korea #South_Korea #Seoul #ImmunoForge #Pemziviptadil #KF1601